Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy
| Autor: | Le H. Hua, Devon S. Conway, Haleigh Harris, Carrie M. Hersh |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Retrospective review
medicine.medical_specialty Neurology business.industry Multiple sclerosis Washout Disease medicine.disease Logistic regression Disease activity 03 medical and health sciences 0302 clinical medicine Natalizumab Internal medicine medicine 030212 general & internal medicine Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of Neurology. 267:2214-2220 |
| ISSN: | 1432-1459 0340-5354 |
| DOI: | 10.1007/s00415-020-09816-1 |
| Popis: | Washout periods (WPs) are increasingly shortened due to concerns of disease rebound when patients on natalizumab are switched to alternative disease-modifying therapies (DMTs). To characterize disease activity outcomes with different WPs when switching from natalizumab. We conducted a retrospective review of patients switching from natalizumab in our MS clinics. Disease activity (relapse, new T2 lesions and/or gadolinium enhancing lesions) between different WPs (days): 0–30, 31–60, and 61–180 were compared, during the first year after switching from natalizumab. To determine predictors of disease activity when switching to any DMT, multivariate logistic regression analysis was used. Post hoc analyses were performed to evaluate the impact of individual DMTs on disease activity. 335 patients discontinued natalizumab with WP: 0–30 (n = 104), 31–60 (n = 113), and 61–180 (n = 136). Disease activity occurred in 44.2% of patients in the 0–30 WP group, 18.6% in the 31–60 WP group, and 27.2% in the 61–180 WP group. There was a significant decrease in odds of disease activity with longer WP when compared to the 0–30 group: 31–60 (OR 0.241, 95% CI 0.108–0.514, p value |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink